Novartis (NYSE: NVS) reported Q2 EPS of $2.41, $0.23 better than the analyst estimate of $2.18. Revenue for the quarter came in at $14.41 billion versus the consensus estimate of $14.17 billion.

Outlook

Net sales expected to grow low single-digit (vs. estimated growth of 0.41% Y/Y) and core operating income expected to decline low single-digit.

For earnings history and earnings-related data on Novartis (NVS) click here.